1-5 of 5
G. Ossenkoppele
Close
Sort by
Journal Articles

A Dendritic Cell Based Vaccination Strategy Geared towards Eradication of Leukemic Stem Cells.

Hetty J Bontkes, Jurjen Ruben, Willemijn van den Ancker, Theresia M Westers, PhD, G. Ossenkoppele, MD, PhD, A. A van de Loosdrecht
Journal: Blood
Blood (2009) 114 (22): 2046.
https://doi.org/10.1182/blood.V114.22.2046.2046
Published: 2009
Journal Articles

High Expression of Decoy Receptor TRAIL-R3 on AML Blasts Is Associated to Shortened Overall Survival. TRAIL-R3 Induced Apoptosis Resistance Can Be Overcome by Specifically Targeting TRAIL-R2 in Vitro

Martine Chamuleau, MD, Linda van Dreunen, S.M.G. Jirka, A. Zevenbergen, G. Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2946.
https://doi.org/10.1182/blood.V112.11.2946.2946
Published: 2008
Journal Articles

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

B. Lowenberg, MD, F. Davies, MD, C. Müller-Tidow, MD, Ulrich Dührsen, A. Burnett, MD, FRCP, P. Zachée, MD, PhD, D. Dierickx, MD, C. Jenkins, MD, P. Sonneveld, MD, M. Jongen-Lavrencic, MD, S. Zweegman, MD, G. Morgan, MD, U. Krug, MD, A. Richardson, PhD, L. Hooftman, MD, G. Ossenkoppele, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 961.
https://doi.org/10.1182/blood.V112.11.961.961
Published: 2008
Journal Articles

Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.

T.M. De Witte, MD, A. Hagemeijer, MD, S. Suciu, PhD, A. Belhabri, MD, M. Delforge, MD, C. Aul, MD, M. Aivado, MD, D. Selleslag, MD, H. Schouten, MD, A. Ferrant, MD, H. Biersack, MD, S. Amadori, MD, P. Muus, MD, U. Jehn, MD, F. Beeldens, J. Jansen, PhD, E. Hellstrom-Lindberg, MD, T. Kovacsovics, MD, U. Hess, MD, P. Wijermans, MD, G. Ossenkoppele, MD, A. Gratwohl, MD, J.-P. Marie, MD, R. Willemze, MD
Journal: Blood
Blood (2005) 106 (11): 794.
https://doi.org/10.1182/blood.V106.11.794.794
Published: 2005
Journal Articles

Use of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Chemotherapy in Patients Aged 61 Years and Older With Acute Myeloid Leukemia (AML): Final Report of AML-11, a Phase III Randomized Study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)

B. Löwenberg, S. Suciu, E. Archimbaud, G. Ossenkoppele, G.E.G. Verhoef, E. Vellenga, P. Wijermans, Z. Berneman, A.W. Dekker, P. Stryckmans, H. Schouten, U. Jehn, P. Muus, P. Sonneveld, M. Dardenne, R. Zittoun
Journal: Blood
Blood (1997) 90 (8): 2952–2961.
https://doi.org/10.1182/blood.V90.8.2952
Published: 1997